|Year : 2018 | Volume
| Issue : 3 | Page : 267-269
A case of choroidal osteoma in a 17-year-old female
Mahdi Almubarak1, Rawan Almubarak2, Saleh Aljaroudi3
1 Retina Division, Dhahran Eye Specialist Hospital, Dhahran, Saudi Arabia
2 College of Medicine, University of Dammam, Dammam, Saudi Arabia
3 Department of Optometry, Dhahran Eye Specialist Hospital, Dhahran, Saudi Arabia
|Date of Web Publication||29-Oct-2018|
Dr. Mahdi Almubarak
Retina Division, Dhahran Eye Specialist Hospital, Dhahran
Source of Support: None, Conflict of Interest: None
| Abstract|| |
A 17-year female was referred for complaints of blurring and decreased vision in the right eye. The patient underwent fundus examination, optical coherence tomography and B-scan ultrasonography. A well-defined, yellow-orange colored lesion was present in the posterior pole. This lesion created an echodense lesion on B-scan even with low gain. The patient was diagnosed with choroidal neovascularization (CNV) associated with choroidal osteoma. The patient was treated with seven consecutive intravitreal anti-vascular endothelial growth factor (VEGF) injections over 14 months. Intravitreal anti-VEGF was effective for CNV associated with choroidal osteoma. Long- term follow-up is necessary to resolve the fluids, possible development of CNV, and possible of bilateral occurrence.
Keywords: Anti-vascular endothelial growth factor, choroidal mass, choroidal neovascularization, choroidal osteoma
|How to cite this article:|
Almubarak M, Almubarak R, Aljaroudi S. A case of choroidal osteoma in a 17-year-old female. Oman J Ophthalmol 2018;11:267-9
| Introduction|| |
Choroidal osteoma, first described by Gass et al. in 1978 as a benign ossifying tumor of unknown etiology, is characterized by a slightly irregular elevated yellow–white lesion that typically occurs in healthy females in their early twenties or thirties., It occurs unilateral in approximately 80% of cases and is located in the posterior pole. Its diagnoses is based on fundus fluorescein angiography (FFA) and B-scan ultrasound. Associated complications include choroidal neovascularization (CNV) and subretinal hemorrhage. To date, no associations have been reported with ocular or systemic diseases; however, some reports suggest links with Stargard's and polypoidal maculopathies.
| Case Report|| |
We report the case of a 17-year-old female who presented to the hospital with complaints of blurring and decreased vision and loss of part of temporal visual field in the right eye. The patient had no systemic disease or family history of retinal lesions. Her visual acuity was 20/125 and 20/20 in the right and left eyes, respectively. The anterior segment was unremarkable bilaterally. Fundus examination of the right eye revealed a subretinal orange 4 × 3 disc diameter lesion with irregular distinct margins located in the superior retina with partial macular involvement [Figure 1]a and [Figure 1]b. The fundus examination of the left eye was unremarkable. B-scan indicated an echodense lesion sized 7.2 mm × 8.3 mm × 1.1 mm, with thick choroidal hemorrhage, strong shadowing, and subretinal calcification next to the optic disc. FFA showed dye leakage in the foveal region (CNV) and dye staining in an area of chronic retinal pigment epithelium (RPE) decompensation overlying the lesion [Figure 2]. This hyperfluorescence progressively increased in intensity in the mid-to-late phase. FFA indicated no feeder vessels. Fourier-domain optical coherence tomography (FD-OCT) indicated hyperreflectivity and subretinal fluid [Figure 3]a and [Figure 3]b. Unilateral choroidal osteoma with secondary CNV was confirmed.
|Figure 1: Fundus examination: Right eye peripapillary juxtafoveal osteoma of the choroid measures 3 to 4 times disc diameters and is associated with subfoveal choroidal neovascularization (a). After treatment of four consecutive intravitreal anti-vascular endothelial growth factor injections with anatomical improvement over more than 1 year of follow-up (b)|
Click here to view
|Figure 2: Fundus fluorescein angiography at 35-s transit reveals dye leakage in the foveal region (choroidal neovascularization) and dye staining in the area of chronic retinal pigment epithelium decompensation overlying the choroidal osteoma|
Click here to view
|Figure 3: Spectral- or Fourier-domain optical coherence tomography: a wide range of tumor reflectivity patterns was demonstrated from hyporeflective to isoreflective to hyperreflective; photoreceptor loss was noted over the decalcified areas (a). After four consecutive intravitreal treatment with anti-vascular endothelial growth factor injections (b)|
Click here to view
Treatment was started with intravitreal anti-vascular endothelial growth factor (VEGF) injection; no laser treatment was performed. The patient received intravitreal anti-VEGF injection every 2 months. OCT was performed at each visit, indicating subretinal fluid. After 6 months, the clinical examination indicated a dry macular that was confirmed with OCT. There was functional improvement and anti-VEGF injection continued for a total of seven injections over a period of almost 14 months. At the last visit, FFA indicated a stable dry macula, no CNV. The lesion size and vision were stable. The patient remains under observation.
| Discussion|| |
Although choroidal osteoma is a benign lesion, calcification occurs mostly in the subretinal space disrupting the RPE due to CNV with permanent loss of vision. Currently, there is no standard treatment for choroidal osteoma. Hence, treatment is targeted toward resolving subretinal fluid and management of CNV. Recent studies have reported that anti-VEGF injection was effective in resolving choroidal vessels, regression of CNV with improvement of vision, and varying duration of follow-up. The characteristics of the lesion and patient response may determine the frequency of anti-VEGF injections. Improvement in vision depends on the location of the lesion, decalcification, RPE involvement, presence of CNV, and resolution of subretinal fluid and hemorrhages. Long-term follow-up is necessary to resolve the fluids, possible development of CNV, and possible of bilateral occurrence.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient's patents have given their consent for the patient's images and other clinical information to be reported in the journal. The patient's patents understand that the patient's name and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Shields CL, Sun H, Demirci H, Shields JA. Factors predictive of tumor growth, tumor decalcification, choroidal neovascularization, and visual outcome in 74 eyes with choroidal osteoma. Arch Ophthalmol 2005;123:1658-66.
Alameddine RM, Mansour AM, Kahtani E. Review of choroidal osteomas. Middle East Afr J Ophthalmol 2014;21:244-50.
] [Full text]
Behera M, Das MK. A case of choroidal osteoma in a 10-year-old child. Int Med Case Rep J 2015;8:273-5.
Fine HF, Ferrara DC, Ho IV, Takahashi B, Yannuzzi LA. Bilateral choroidal osteomas with polypoidal choroidal vasculopathy. Retin Cases Brief Rep 2008;2:15-7.
Kubota-Taniai M, Oshitari T, Handa M, Baba T, Yotsukura J, Yamamoto S, et al.
Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma. Clin Ophthalmol 2011;5:1051-5.
[Figure 1], [Figure 2], [Figure 3]